Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
04 March 1998Website:
http://www.surmodics.comNext earnings report:
31 January 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 14 Nov 2024 22:41:49 GMTDividend
Analysts recommendations
Institutional Ownership
SRDX Latest News
SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago.
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SurModics (SRDX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.52 per share a year ago.
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc . ( Nasdaq : SRDX ), relating to its proposed sale to GTCR LLC. Under the terms of the agreement, Surmodics, Inc. shareholders will receive $43.00 in cash per share of Surmodics stock they own.
NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc. (Nasdaq: SRDX ), relating to its proposed sale to GTCR LLC.
What type of business is Surmodics?
Surmodics, Inc. - a leading provider of medical devices and diagnostic technologies for healthcare system companies. The main focus is on cardiovascular diseases. The company was founded in 1979. The headquarters is located in the state of Minnesota. Surmodics, Inc. operates in two reporting business segments: the Medical Device Division - designs, develops, and manufactures interventional medical devices, primarily balloons and catheters for the treatment of peripheral artery diseases, urology, and others. The In Vitro Diagnostics Division - produces and sells components for diagnostic immunoassays, molecular tests, biomedical research.
What sector is Surmodics in?
Surmodics is in the Healthcare sector
What industry is Surmodics in?
Surmodics is in the Medical Devices industry
What country is Surmodics from?
Surmodics is headquartered in United States
When did Surmodics go public?
Surmodics initial public offering (IPO) was on 04 March 1998
What is Surmodics website?
https://www.surmodics.com
Is Surmodics in the S&P 500?
No, Surmodics is not included in the S&P 500 index
Is Surmodics in the NASDAQ 100?
No, Surmodics is not included in the NASDAQ 100 index
Is Surmodics in the Dow Jones?
No, Surmodics is not included in the Dow Jones index
When was Surmodics the previous earnings report?
No data
When does Surmodics earnings report?
The next expected earnings date for Surmodics is 31 January 2025